PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls

PARP inhibitors (PARPi) gained major interest among prostate cancer researchers in the last few years, thanks to the outstanding results coming from the PROfound an TRITON2 studies. Following that, PARPi gained approval also in metastatic, castration-resistant prostate cancer (mCRPC) with mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Franza, A., Claps, M., Procopio, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591349/
https://www.ncbi.nlm.nih.gov/pubmed/34763215
http://dx.doi.org/10.1016/j.tranon.2021.101263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591349/
https://www.ncbi.nlm.nih.gov/pubmed/34763215
http://dx.doi.org/10.1016/j.tranon.2021.101263

Ejemplares similares